Anti-infective antibodies are being used extensively nowadays to treat serious bacterial and viral diseases such as pneumonia, tuberculosis and malaria. According to the World Health Organization, six major infectious diseases namely diarrhea, pneumonia, malaria, acquired immune deficiency syndrome (AIDS) , measles and tuberculosis are responsible for half of the premature deaths worldwide killing children and young adults. Moreover, threatening pandemics such as H1N1 influenza A virus (swine flu) is also adding pressure on healthcare sector. On the basis of these diseases which are being treated with the help of anti-infective antibodies, Anti-Infective Antibodies Market is divided into four major segments namely recombinant antibodies for viral diseases, recombinant antibodies for bacterial diseases, human plasma-derived immunoglobulins and Varicella Zoster immunoglobulins (VZIG).
Among the mentioned anti-infective antibodies, the major market share is captured by recombinant antibodies for viral diseases followed by recombinant antibodies for bacterial diseases due to high prevalence of these diseases worldwide. According to the World Health Organization reports, 13.3 million people were suffering from AIDS in 2013 all over the world. Among the different antibodies available, the major anti-infective antibodies which are revolutionizing the market include truvada and valtrex, which are anti-HIV and anti-herpes antibodies respectively.
Request to View Brochure of Report -
Additionally, the growing emergence of antibody resistant microorganisms, lethal virus and threat from engineered microorganisms is stimulating the interest of researchers towards developing novel anti-infective antibodies. Advances in understanding the mechanisms and new anti-bodies technologies are also contributing for the growing class of anti-infective antibodies in research and development. In anti-infective antibodies market, large numbers of companies are undergoing clinical trials as for instance, Novaratis AG is performing Phase IIb clinical trials of Albuferon, drug for the treatment of hepatitis C and Roche Pharma AG has announced positive results for PEGASYS combination therapy, treatment for hepatitis C.
Companies based in North America and Europe is extensively performing research and development in anti-infective antibodies segment. The major key players which are involved in production and research and development in anti-infective drugs market include Novaratis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Gilead Sciences, Pfizer, Inc., Abbott Laboratories, Sanofi S.A., Johnson & Johnson and Bristol-Myers Squibb.
Comments
Post a Comment